HPV-Specific Systemic Antibody Responses and Memory B Cells Are Independently Maintained Up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs In...

Overview

Journal Vaccines (Basel)

Date 2020 Jan 18

PMID 31947611

Citations 14

Authors

Francesco Nicoli

Barbara Mantelli

Eleonora Gallerani

Valentina Telatin

Irene Bonazzi

Peggy Marconi

Riccardo Gavioli

Liliana Gabrielli

Tiziana Lazzarotto

Luisa Barzon

Giorgio Palu

And Antonella Caputo

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV) persistent infections are associated with cervical cancer and other HPV-related diseases and tumors. Thus, the characterization of long lasting immunity to currently available HPV vaccines is important. A total of 149 female subjects vaccinated with Cervarix or Gardasil participated to the study and they were stratified according to age (10-12-year-old and 16-20-year-old). Humoral immune responses (IgG and neutralizing antibody titers, antibody avidity) and circulating memory B cells were analyzed after an average of 4-6 years from the third immunization. The humoral responses against HPV-16 and HPV-18 (and HPV-6 and HPV-11 for Gardasil) were high in both age groups and vaccines up to six years from the third dose. However, Cervarix induced significantly higher and more persistent antibody responses, while the two vaccines were rather equivalent in inducing memory B cells against HPV-16 and HPV-18. Moreover, the percentage of subjects with vaccine-specific memory B cells was even superior among Gardasil vaccinees and, conversely, Cervarix vaccinated individuals with circulating antibodies, but undetectable memory B cells were found. Finally, a higher proportion of Cervarix-vaccinated subjects displayed cross-neutralizing responses against non-vaccine types HPV-31 and HPV-45. Gardasil and Cervarix may, thus, differently affect long-lasting humoral immunity from both the quantitative and qualitative point of view.

Citing Articles

Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development.

Mardanova E, Vasyagin E, Ravin N Plants (Basel). 2025; 13(24.

PMID: 39771262 PMC: 11678810. DOI: 10.3390/plants13243564.

Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study.

Tian X, Weng D, Chen Y, Wang Y, Li X, Wang X J Natl Cancer Cent. 2024; 4(4):311-317.

PMID: 39735440 PMC: 11674434. DOI: 10.1016/j.jncc.2024.08.001.

Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV.

Losada C, Samaha H, Scherer E, Kazzi B, Khalil L, Ofotokun I Vaccines (Basel). 2023; 11(6).

PMID: 37376456 PMC: 10301114. DOI: 10.3390/vaccines11061067.

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.

Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P NPJ Vaccines. 2023; 8(1):39.

PMID: 36922512 PMC: 10017795. DOI: 10.1038/s41541-023-00628-8.

Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.

Loos C, Coccia M, Didierlaurent A, Essaghir A, Fallon J, Lauffenburger D NPJ Vaccines. 2023; 8(1):34.

PMID: 36890168 PMC: 9992919. DOI: 10.1038/s41541-023-00613-1.

References

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

Wheeler C, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Perez G . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009; 199(7):936-44. DOI: 10.1086/597309. View

Telatin V, Nicoli F, Frasson C, Menegotto N, Barbaro F, Castelli E . In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment. Front Cell Infect Microbiol. 2019; 9:190. PMC: 6588015. DOI: 10.3389/fcimb.2019.00190. View

Crotty S, Aubert R, Glidewell J, Ahmed R . Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004; 286(1-2):111-22. DOI: 10.1016/j.jim.2003.12.015. View

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1343-58. PMC: 3338932. DOI: 10.4161/hv.7.12.18281. View

Winer R, Lee S, Hughes J, Adam D, Kiviat N, Koutsky L . Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157(3):218-26. DOI: 10.1093/aje/kwf180. View

Nygard M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M . Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015; 22(8):943-8. PMC: 4519713. DOI: 10.1128/CVI.00133-15. View

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1359-73. PMC: 3338933. DOI: 10.4161/hv.7.12.18282. View

Dauner J, Pan Y, Hildesheim A, Kemp T, Porras C, Pinto L . Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes. 2012; 26(2):73-80. PMC: 3319198. DOI: 10.1016/j.mcp.2012.01.002. View

10.

Herrera D, Rojas O, Duarte-Rey C, Mantilla R, Angel J, Franco M . Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab. PLoS One. 2014; 9(5):e97087. PMC: 4018270. DOI: 10.1371/journal.pone.0097087. View

11.

Nguyen D, Joyner C, Sanz I, Lee F . Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells. Front Immunol. 2019; 10:2138. PMC: 6749102. DOI: 10.3389/fimmu.2019.02138. View

12.

Toh Z, Kosasih J, Russell F, Garland S, Mulholland E, Licciardi P . Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019; 12:1951-1967. PMC: 6613616. DOI: 10.2147/IDR.S178381. View

13.

Nardelli-Haefliger D, Wirthner D, Schiller J, Lowy D, Hildesheim A, Ponci F . Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 2003; 95(15):1128-37. DOI: 10.1093/jnci/djg018. View

14.

Munoz N, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. DOI: 10.1093/jnci/djp534. View

15.

Stanley M . HPV vaccination in boys and men. Hum Vaccin Immunother. 2014; 10(7):2109-11. PMC: 4186028. DOI: 10.4161/hv.29137. View

16.

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

17.

Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View

18.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

19.

Einstein M, Levin M, Chatterjee A, Chakhtoura N, Takacs P, Catteau G . Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014; 10(12):3455-65. PMC: 4514093. DOI: 10.4161/hv.36117. View

20.

Schmeler K, Sturgis E . Expanding the benefits of HPV vaccination to boys and men. Lancet. 2016; 387(10030):1798-9. DOI: 10.1016/S0140-6736(16)30314-2. View